Ch07_09_combo_present_Cho_Final

Firms eg medtronic eg teva pharmaceuticals cephalon

Info iconThis preview shows page 1. Sign up to view the full content.

View Full Document Right Arrow Icon
This is the end of the preview. Sign up to access the rest of the document.

Unformatted text preview: ducts that are new to the firm. current • New ventures/products require an average of 8 years to New achieve profitability achieve • About 88% of new products fail – Returns are more predictable because of the acquired Returns firms’ experience with the products. firms’ – E.g., Medtronic – E.g., Teva Pharmaceuticals + Cephalon 1–12 Acquisitions: Lower Risk Compared to Developing New Products • An acquisition’s outcomes can be estimated An more easily and accurately than the outcomes of an internal product development process. an – Managers may view acquisitions as lowering risk Managers associated with internal ventures and R&D investments. investments. – E.g., Teva Pharmaceuticals + Cephalon 1–13 Acquisitions: Increased Diversification • Using acquisitions to diversify a firm is the Using quickest and easiest way to change its portfolio of businesses. of • Both related diversification and unrelated Both related diversification strategies can be implemented through acquisitions. through • The more related the acquired firm is to the The acquiring firm, the greater is the probability that the acquisition will be successful. the...
View Full Document

This note was uploaded on 04/28/2013 for the course MGMT 491 taught by Professor S.cho during the Spring '12 term at Washington State University .

Ask a homework question - tutors are online